VIGL - Vigil Neuroscience, Inc. Stock Price, Fair Value and News

$8.05

Market Closed as of 05 Aug 2025, 04:00 pm ET

VIGL Stock Valuation Analysis

Valuation

Max Portfolio %

VIGL Price Action

VIGL RSI Chart

VIGL Stock Valuation Analysis

Valuation

Max Portfolio %

VIGL Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VIGL Fundamentals

VIGL Earnings

VIGL Profitability

VIGL Investor Care

Revenue & Growth

About Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
WEBSITE	vigilneuro.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	61